BeiGene Announces Supply Update for ABRAXANE® in China
BeiGene, Ltd. - American Depositary Shares (BGNE)
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beigene.com/phoenix.zhtml?c=254246&p=irol-irhome_pf
Company Research
Source: GlobeNewswire
- NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company - As the marketing agent for ABRAXANE in China, BeiGene is working with BMS to restore supply in China BEIJING, China, and CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, on March 25, 2020, the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in China supplied to BeiGene by Celgene Corporation, a Bristol Myers Squibb (BMS) company. This suspension is based on inspection findings at BMS’s contract manufacturing facility in the United States. As a result, BeiGene expects a disruption in ABRAXANE supply in
Show less
Read more
Impact Snapshot
Event Time:
BGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BGNE alerts
High impacting BeiGene, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BGNE
News
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual MeetingBusiness Wire
- BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $235.00 to $236.00. They now have a "buy" rating on the stock.MarketBeat
- With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners [Yahoo! Finance]Yahoo! Finance
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
BGNE
Earnings
- 2/26/24 - Beat
BGNE
Sec Filings
- 4/23/24 - Form 8-K
- 4/15/24 - Form PRE
- 4/11/24 - Form 4
- BGNE's page on the SEC website